Novo Nordisk and Eli Lilly are the Beneficiaries of Cigna's Price cap!
Insurers make Wegovy & Co. affordable
GLP-1 becomes mass-marketable – and Novo is leading the way!
Reading Time: 1 minute
The GLP-1 market leaders are gaining momentum: Thanks to Cigna's $200 cap for Wegovy and Zepbound, the original medications are becoming more accessible. Cigna's decision to limit the monthly out-of-pocket costs for Wegovy & Zepbound to $200 is a strategic boost for Novo Nordisk and Eli Lilly. The expensive GLP-1 medications are now suddenly affordable for millions of insured individuals – which is likely to noticeably increase the demand for original preparations. The obesity market is expected to grow to over $200 billion by 2030 according...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
